Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 20201
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2021.03.08.21253009: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: All household members were eligible for inclusion if they or their guardian provided written consent to participate, were at least 1 year of age, and had lived in the area at least 1 week before the survey, regardless of current or past illness.
IRB: The study protocol was approved by South Sudan Ministry of Health Ethics Review Board.Randomization Three sampled EAs inhabited by families of military personnel were randomly replaced due to denied access. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Laboratory analysis: DBS were eluted and tested for the presence of … SciScore for 10.1101/2021.03.08.21253009: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: All household members were eligible for inclusion if they or their guardian provided written consent to participate, were at least 1 year of age, and had lived in the area at least 1 week before the survey, regardless of current or past illness.
IRB: The study protocol was approved by South Sudan Ministry of Health Ethics Review Board.Randomization Three sampled EAs inhabited by families of military personnel were randomly replaced due to denied access. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Laboratory analysis: DBS were eluted and tested for the presence of anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies targeting the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 using a quantitative enzyme-linked immunosorbent assay (ELISA) previously developed and validated at Massachusetts General Hospital [25]. anti-SARS-CoV-2 immunoglobulin G (IgGsuggested: NoneThis assay quantifies RBD-specific antibody concentrations (μg/mL) using IgG-specific anti-RBD monoclonal antibodies, and the full protocol used for eluting DBS samples for the ELISA are detailed online [26]. anti-RBDsuggested: NoneResults from OddPub: Thank you for sharing your code and data.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:This study has several limitations. As described above, our positive control data came from a cohort in Boston, USA. Thus, despite our efforts to correct for differences between the populations, we do not know how accurate our sensitivity estimates are for Juba, or anywhere on the African continent. In addition, we used a single ELISA that measured IgG antibodies targeting the RBD of SARS-CoV-2’s spike protein. Previous studies have shown variation in sensitivity and specificity of antibody assays that target different antigens [15,47], suggesting that using multiple antigens may provide a better picture of seroprevalence than a single antigen alone, particularly when validation data are not available from the local population. While the study had a standard definition for households, the study team faced challenges in implementing this strict definition, so we were unable to confidently estimate the degree to which SARS-CoV-2 infections clustered within households or to adjust for this in the regression model. In addition, many shelters originally selected using satellite imaging were empty and we had to select alternative households, which increased the time required to complete the survey. Finally, while this study was representative of the residential neighborhoods of Juba, the sample did not include more than 30,000 estimated internally displaced persons living in two of Juba’s IDP camps [48]. Nevertheless, 14.3% of households participating in the study reported to be ID...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
